|5-((5-(2-(3-(3-氨基丙氧基)-6-甲氧基苯基)-1H-吡唑-3-基)氨基)吡嗪-2-甲腈二盐酸盐|CsnPharm

CAS No.: 1234015-54-3

Prexasertib 2HCl Catalog No. CSN17600

Synonyms: LY2606368 dihydrochloride;Prexasertib 2HCl;Prexasertib HCl

LY2606368 (Prexasertib) is a selective Chk1 inhibitor with IC50 value <1nM, modest to Chk2 and Rsk with IC50 values of 8nM and <10nM.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

靶点 Chk1

IC50:1.5nM
描述In the presence of DNA damage, Chk1 (checkpoint kinase 1) can be activated through phosphorylation by ATR and then lead to the phosphorylation and degradation of CDC25A, the nuclear exclusion of CDC25B and CDC25C. Through Chk1-mediated loss of CDC25A activity, CDK2 in an inactive phosphorylated state blocking initiation of DNA replication origins can be suspended. Cytosolic sequestration of CDC25B and CDC25C prevents the activation of CDK1 resulting in cell-cycle arrest at the G2–M boundary. Thus, Chk1 acts as a key regulator to maintain functional intra-S and G2–M checkpoints. LY2606368 (Prexasertib) is a selective Chk1 inhibitor with IC50 value <1nM, modest to Chk2 and Rsk with IC50 values of 8nM and <10nM (measured by enzymatic assay). LY2606368 potently abrogated the G2–M checkpoint activated by doxorubicin in p53-deficient HeLa cells with an EC50 of 9 nM. Treatment with 33-100nM LY2606368 for 7h resulted in DNA damage, revealed by TUNEL or increased pH2AX-S139, in HeLa cells during S-phase. When U-2 OS cells, depleted of CDC25A or CDK2 through siRNA, were treated for 6 hours with 4nM LY2606368, H2AX phosphorylation was greatly reduced relative to LY2606368 alone. This indicated that the DNA damage effects of inactivation of Chk1 by LY2606368 were dependent upon CDC25A and CDK2. Treatment with 33nM LY2606368 for a total of 12 hours caused replication catastrophe in HeLa cells. Subcutaneous injection of 1, 3.3, or 10 mg/kg of LY2606368 twice daily for 3 days followed by 4 days of rest for three cycles caused statistically significant tumor growth inhibition (up to 72.3%) in mice bearing Calu-6 xenograft tumors^[1]. Several phase 2 studies of LY2606368 treatment for small cell lung cancer, ovarian cancer, breast cancer and prostate cancer are under recruiting now (see https://www.clinicaltrials.gov/).
作用机制LY2606368 is an ATP-competitive protein kinase inhibitor with a Ki of 0.9nM against purified Chk1.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.2815 mL
- 11.4074 mL
- 22.8149 mL
- 5 mM
- 0.4563 mL
- 2.2815 mL
- 4.5630 mL
- 10 mM
- 0.2281 mL
- 1.1407 mL
- 2.2815 mL

技术信息

CAS号

1234015-54-3

储存条件

粉末: Inert atmosphere,Store in freezer, under -20°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C18H21Cl2N7O2

运输

蓝冰

分子量

438.31

别名

LY2606368 dihydrochloride;Prexasertib 2HCl;Prexasertib HCl;LY-2606368 HCl

溶解度

DMSO	7.4 mg/mL (16.9 mM)
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Prexasertib 2HCl Catalog No. CSN17600

靶点选择性

请登录您的专属账户

确认信息